Top Markets
#1 Pleasing Gold Pleasing Gold +1,542.01%
#2 PulseChain PulseChain +58.48%
#3 Merlin's Seal BTC Merlin's Seal BTC +32.90%
#4 BOOK OF MEME BOOK OF MEME +31.87%
#5 Ontology Gas Ontology Gas +23.58%
#6 Pump.fun Pump.fun +22.86%
#7 Nockchain Nockchain +22.84%
#8 Unit Pump Unit Pump +22.48%
#9 Neiro Neiro +20.67%
#10 SkyAI SkyAI +20.01%
Coin of the day
Pleasing Gold Pleasing Gold
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Entropy Neurodynamics Limited Entropy Neurodynamics Limited

Entropy Neurodynamics Limited

ENP
Rangering i aksjer #26484
Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical... Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical company, dedicated to pioneering novel formulations for psilocin administration. These formulations are intended for use alongside psychotherapy, aiming to tackle medical conditions with pressing unmet needs across Australia, Canada, Switzerland, and the United States. The firm's flagship development is TRP-8803, an intravenously infused psilocin formulation that has successfully concluded Phase 2 clinical trials. These trials investigated its potential to treat binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. Additionally, the company is advancing TRP-8802, a synthetic, orally administered psilocybin compound. TRP-8802 is currently undergoing Phase 2a clinical trials for binge eating and is in Phase 2 clinical development for fibromyalgia and irritable bowel syndrome. Established in 2019 and headquartered in Camberwell, Australia, the company adopted its current name, Entropy Neurodynamics Limited, in November 2025, having previously operated as Tryptamine Therapeutics Limited.
Aksjekurs
$0.02468497
Sist synkronisert: 2026-07-30
Markedsverdi
$40.28M
Endring (1 dag)
0.00%
Endring (1 år)
-
Land
AU
Handel Entropy Neurodynamics Limited (ENP)

Kategori

Healthcare
P/E-forhold for Entropy Neurodynamics Limited (ENP)
P/E-forhold per 2026 TTM: 0
Ifølge Entropy Neurodynamics Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Entropy Neurodynamics Limited fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.